

# Metabolic pathways of acylcarnitine synthesis

Jana Brejchova<sup>1</sup>, Kristyna Brejchova<sup>1</sup>, Ondrej Kuda<sup>2</sup>

<sup>1</sup>Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia;

<sup>2</sup>Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia;  
orcid.org/ 0000-0001-7034-4536; corresponding author [ondrej.kuda@fgu.cas.cz](mailto:ondrej.kuda@fgu.cas.cz)

## Abstract

Acylcarnitines are important markers in metabolic studies of many diseases, including metabolic, cardiovascular, and neurological disorders. We reviewed analytical methods for analyzing acylcarnitines with respect to the available structural information, the technical limitations of older methods, and the potential of new mass spectrometry-based techniques to provide new information on metabolite structure. We summarized the nomenclature of acylcarnitines based on historical common names and common abbreviations, and we propose the use of systematic abbreviations derived from the shorthand notation for lipid structures. The transition to systematic nomenclature will facilitate acylcarnitine annotation, reporting, and standardization in metabolomics. We have reviewed the metabolic origins of acylcarnitines important for the biological interpretation of human metabolomic profiles. We identified neglected isomers of acylcarnitines and summarized the metabolic pathways involved in the synthesis and degradation of acylcarnitines, including branched-chain lipids and amino acids. We reviewed the primary literature, mapped the metabolic transformations of acyl-CoAs to acylcarnitines, and created a freely available WikiPathway WP5423 to help researchers navigate the acylcarnitine field. The WikiPathway was curated, metabolites and metabolic reactions were annotated, and references were included. We also provide a table for conversion between common names and abbreviations and systematic abbreviations linked to the LIPID MAPS or Human Metabolome Database.

**Keywords:** acylcarnitines; mass spectrometry; beta oxidation; branched fatty acids; branched lipids; nomenclature; standardization; shorthand notation for lipid structures; LIPID MAPS

## Introduction

Acylcarnitines are acyl esters of carnitine (L-3-hydroxy-4-aminobutyrobetaine) and are essential for the oxidative catabolism of fatty acids in mitochondria and peroxisomes. They are necessary for healthy and sustainable cellular energy homeostasis, involved in the metabolism of branched-chain amino acids and related metabolic pathways, and serve as a detoxification pathway<sup>1,2</sup>. There are many acylcarnitine molecules described in public databases of metabolites, for instance, 114 records in LIPID MAPS, 2359 records in the Human Metabolome Database, and 308 entries on the ChEBI database, measured in plasma/serum, dried blood spots, urine, bile and amniotic fluid<sup>3</sup>, but very little is published about their metabolic origins.

We aimed to help researchers interpret metabolomics data containing acylcarnitines. We reviewed the biologically important acylcarnitines<sup>1</sup> concerning their biochemical origins and generated a pathway map summarizing the reactions. We focused on the isomers and nomenclature and annotated the enzymatic reactions involved in their metabolism. This review should facilitate orientation in the acylcarnitine datasets and link the measured analytes with the correct enzymatic reactions.

## Analytical methods using mass spectrometry

Critical evaluation of the limitations of the analytical techniques used to measure acylcarnitine is the basis for correct annotation and biological interpretation.

Sample extraction should consider that the polarity of acylcarnitines can vary by more than 10 orders of magnitude on the log octanol-water partition coefficient (logP) scale. In commonly employed bi-phase extraction methods like methyl *tert*-butyl ether/methanol/water, chloroform/methanol/water, and dichloromethane/methanol/water, it is crucial to analyze both fractions to cover these metabolites <sup>4</sup>.

Direct-infusion tandem mass spectrometry (MS) remains a valid approach for identifying patients with inborn errors of metabolism, problems in mitochondrial fatty acid  $\beta$ -oxidation, and certain types of acidemias (reviewed by Miller et al. <sup>3</sup>). However, this technique provides only limited information about the analytes, usually the number of carbon atoms and double bonds.

Currently, liquid chromatography-mass spectrometry (LC-MS) is the most common technique for metabolomics profiling, which allows the separation of acylcarnitine isomeric species and improves the sensitivity and selectivity of their detection <sup>1,3</sup>. Although LC-MS provides an insight into the analyte's structure, it does not yield unambiguous molecular identity.

Recent advances in analytical techniques push forward our ability to provide a full structural characterization of lipid species in complex biological matrices. These include ion mobility spectrometry, ion activation techniques, and derivatizations <sup>5-8</sup>, which allow quantification of isomeric and odd-numbered acylcarnitines, identification of acyl double bond position and configuration, stereochemistry, etc. In the future, these specialized techniques will become a part of routine pipelines, producing hundreds of acylcarnitine species structurally identified at a molecular level. New tools will be needed to mine these information-rich datasets.

## Acylcarnitine nomenclature

### Common names

According to IUPAC, the common names of acyl groups are typically derived by replacing the **-ic** acid suffix of the corresponding carboxylic acid's common name with **-yl** (acetic acid > acetyl- or palmitic acid > palmityl-). Systematic names based on hydrocarbon chains are derived by replacing the **-ic** acid suffix with **-oyl** (hexadecanoic acid > hexadecanoyl-)—for instance, acetylcarnitine and hexadecanoylcarnitine.

### Common abbreviations

Common name acylcarnitine abbreviations in the field of newborn screening are simple and follow these rules: a) a number of all carbon atoms is used to describe the chain length regardless of the branching or functional groups (e.g., glutarylcarnitine as C5-DC); b) unsaturation degree is used only when present (e.g., oleoylcarnitine as C18:1); c) functional groups are used without the positional information (e.g. 3(*S*)-hydroxybutyrylcarnitine as C4-OH) <sup>3,9</sup>. Alternative grammar distinguishes isomeric species, e.g., 3-hydroxybutyrylcarnitine and 3-hydroxyisobutyrylcarnitine as C4-OH and C4-OH-I, respectively <sup>1</sup>. The *iso* prefix can be used for structures where the saturated chain has a branching point on the penultimate (one from the end) carbon atom (e.g., isobutyrylcarnitine). The *anteiso* prefix marks the branching point located on the antepenultimate carbon atom (two from the end). The prefixes cannot be used with unsaturated or modified chains, and the position of the methyl branching group is used instead (e.g., tiglylcarnitine as C5:1-M).

### Systematic abbreviations

Common names and abbreviations will soon reach their limit of usability. Abbreviations based on systematic names are needed due to the advent of more powerful analytical techniques. Nowadays, rules designed for unit-resolution mass spectrometers cannot describe structural diversity. Shorthand notation for lipid structures<sup>10-12</sup> allows annotation of the measured analytes based on the level of structural information provided by the analytical technique. It combines predefined class (CAR) followed by the acyl chain characteristics, including all available structural information. For instance, there are at least four different decenoylcarnitines: CAR 10:2(2*E*), CAR 10:1(3*E*), CAR 10:1(3*Z*), and CAR 10:1(4*Z*) in the  $\beta$ -oxidation pathways of common fatty acids (Figure 1). Two of them, CAR 10:1(3*Z*) and CAR 10:1(2*E*), come from  $\beta$ -oxidation of palmitoleic acid (9*Z*). However, there are at least 15 different isomers of fatty acid 16:1 in human plasma, four containing a double bond at positions 9, 10, and 11<sup>6</sup>. Therefore, many more CAR 10:1 isomers from the FA 16:1 or other longer FAs could be present in plasma as yet unidentified but describable by shorthand notation. However, this approach is also limited based on predefined classes. It is impossible to distinguish the L-/D- isomers within the CAR class definition, and a full IUPAC name is the ultimate option.

The systematic abbreviations are backward compatible. Newborn screening acylcarnitine data can be correctly annotated, and metabolomic profiling data, acquired using innovative derivatization or fragmentation techniques, can be annotated with all structural details<sup>6,7</sup>. Broader acceptance of the shorthand notation by major databases would facilitate acylcarnitine annotations, standardization, and further data processing via overrepresentation analysis<sup>13</sup>.




Figure 1. Acylcarnitine pathways. (A) β-oxidation of straight fatty acids; (B) β-oxidation of straight polyunsaturated fatty acids; (C) β-oxidation of dicarboxylic fatty acids; (D) β-oxidation of odd-chain fatty

acids; (E) Ketogenic pathway; (F) Metabolism of branched-chain amino acids; (G) Degradation of amino acids; (H)  $\beta$ -oxidation of branched-chain fatty acids; (I) Metabolism of amino acids and short-chain acylcarnitines. See Table 1 for annotations, Figure S1 for large-scale version of the figure, and WikiPathway WP5423 for details.

### Lipid databases and metabolite identities

When discussing the biological effect of acylcarnitines, we need to find the most appropriate identifiers in a database considering the analytical limitations and the biological knowledge. This task is challenging and sometimes possible. For instance, an optimized analytical technique can measure the carnitine ester of palmitic acid at the 'Complete structure level' according to shorthand notation for lipid structures<sup>10,11</sup>. We need to find an identifier for (S)-3-(palmitoyloxy)-4-(trimethylammonio)butanoate, which is the biologically important molecule commonly known as 'palmitoylcarnitine.' First, L-carnitine is essential for mitochondrial  $\beta$ -oxidation, and its optimal isomer, D-carnitine, is a xenobiotic compound<sup>14,15</sup>. Therefore, in most cases, only 'L'-acylcarnitines (or (R)- according to Cahn-Ingold-Prelog rules) are biologically relevant for human metabolism. Second, metabolite databases contain records covering different levels of knowledge of metabolite structure (Table 1). Some records lack stereochemistry, and some databases contain the 'D-' forms. Pre-calculated and non-curated databases might also contain wrong records, e.g., LIPID MAPS record LMFA07070079 was up to recently called L-palmitoylcarnitine, which was an incorrect common name for (S)-3-(palmitoyloxy)-4-(trimethylammonio)butanoate aka D-palmitoylcarnitine. The involvement of the community is needed to report and curate database records. The incorrect mapping of database identifiers can affect further data processing, like over-representation or pathway analysis. For instance, the Rhea database contains only 'L'-acylcarnitine reactions (<https://www.rhea-db.org/rhea/12663>), and 'D'-identifiers would produce false negative results.

In parallel, acylcarnitine data measured using direct infusion unit-resolution mass spectrometry yield annotations at 'Species level'<sup>10,11</sup>, and careful identifier mapping should be performed to prevent over-interpretation. For instance, 3-hydroxyisovaleryl carnitine (C5-OH-I), LIPID MAPS identification LMFA07070041, is abbreviated as CAR 5:0;O and the same systematic abbreviation is used for 3-hydroxyvaleryl carnitine. However, these two metabolites come from entirely different pathways and precursors (leucine degradation and odd-chain fatty acid degradation, Figure 1).

### Acylcarnitines important for biological interpretation of human metabolomic profiles

Recently, Dambrova et al. published an excellent review on acylcarnitines<sup>1</sup>. We decided to update the older acylcarnitine nomenclature (based on newborn screening rules) into systematic nomenclature and map the metabolites associated with a disease or necessary for the biological interpretation of datasets into identifiers and pathways (Table 1, Figure 1). We primarily focused on the identity and source of acylcarnitines and successfully mapped most of the metabolites. However, some acylcarnitines defined by newborn screening methods cannot be unambiguously identified<sup>9</sup>.

Although the 3-hydroxydecanoylcarnitine (C10:1-OH) has been officially part of the newborn screening panel<sup>3,9</sup>, we could not find its molecular identity. It is not a product of the major metabolic pathways, and the position of the double bond is unknown. Violante et al. performed a detailed analysis of mitochondrial carnitine acyltransferase substrate preference and showed that the acyltransferase enzyme for some short-chain-CoAs is still unknown. For instance, an enzyme(s) responsible for the synthesis of succinylcarnitine, malonylcarnitine, or 3-hydroxy-3-methylglutaryl carnitine is still unknown

<sup>16-18</sup>. 3-Hydroxy-3-methylglutaryl carnitine (C5:1-M-OH-DC) was observed only using low-resolution MS, and its molecular identity was not confirmed by other techniques <sup>19</sup>.

Limitations of analytical techniques often prevent accurate identification of the compounds. For instance, isovalerylcarnitine (C5:0-I), which is a diagnostic indicator of isovaleric acidemia, is isobaric with pivaloylcarnitine, 2-methylbutyrylcarnitine, and *n*-valerylcarnitine <sup>20</sup>. Pivaloylcarnitine derived from antibiotics and pimeloylcarnitine synthesized by microbiota are typical members of exposome <sup>20,21</sup>. Mixtures of straight and branched saturated acylcarnitines (e.g., CAR 20:0 as arachidylcarnitine or phytanoylcarnitine) should be considered when annotating unknown features <sup>22,23</sup>.

Table 1 – Biologically important acylcarnitines

Group	Panel	Common abbreviation	Common name	Systematic abbreviation	LIPID MAPS ID
Saturated straight	NBS	C2:0	Acetylcarnitine	CAR 2:0	LMFA07070050
	NBS	C3:0	Propionylcarnitine	CAR 3:0	LMFA07070005
	NBS	C4:0	Butyrylcarnitine	CAR 4:0	LMFA07070003
		C5:0	Valerylcarnitine	CAR 5:0	LMFA07070111
	NBS	C6:0	Caproylcarnitine	CAR 6:0	LMFA07070001
	NBS	C7:0	Heptanoylcarnitine	CAR 7:0	LMFA07070068
	NBS	C8:0	Octanoylcarnitine	CAR 8:0	LMFA07070002
		C9:0	Nonanoylcarnitine	CAR 9:0	LMFA07070082
	NBS	C10:0	Decanoylcarnitine	CAR 10:0	LMFA07070006
		C11:0	Undecanoylcarnitine	CAR 11:0	LMFA07070110
	NBS	C12:0	Lauroylcarnitine	CAR 12:0	LMFA07070062
		C13:0	Tridecanoylcarnitine	CAR 13:0	
	NBS	C14:0	Myristoylcarnitine	CAR 14:0	LMFA07070107
		C15:0	Pentadecanoylcarnitine	CAR 15:0	
	NBS	C16:0	Palmitoylcarnitine	CAR 16:0	LMFA07070004
	NBS	C18:0	Stearoylcarnitine	CAR 18:0	LMFA07070008
		C22:0	Behenoylcarnitine	CAR 22:0	LMFA07070089
		C24:0	Lignoceroylcarnitine	CAR 24:0	
	C26:0	Cerotoylcarnitine	CAR 26:0	LMFA07070069	
Unsaturated straight	NBS	C3:1	Propenoylcarnitine	CAR 3:1(2E)	LMFA07070104
		C4:1	Butenylcarnitine	CAR 4:1(2E)	LMFA07070053
		C5:1	2-Pentenoylcarnitine	CAR 5:1(2E)	
		C6:1	Hexenoylcarnitine	CAR 6:1(2E)	LMFA07070031
	NBS	C8:1	Octenoylcarnitine	CAR 8:1(2E)	LMFA07070035
	NBS	C10:1	Decenoylcarnitine	CAR 10:1(2E)	
				CAR 10:1(3E)	
				CAR 10:1(3Z)	
				CAR 10:1(4Z)	LMFA07070017
NBS	C10:2	Decadienoylcarnitine	CAR 10:2(2E,4Z)	LMFA07070015	

	NBS	C12:1	Dodecenoylcarnitine	CAR 12:1(2E)		
				CAR 12:1(3Z)		
				CAR 12:1(5Z)		
		C12:2	Dodecadienoylcarnitine	CAR 12:2(2E,5Z)		
				CAR 12:2(2E,6Z)		
				CAR 12:2(3Z,6Z)		
	NBS	C14:1	Tetradecenoylcarnitine	CAR 14:1(2E)		
				CAR 14:1(5Z)	LMFA07070057	
				CAR 14:1(7Z)		
	NBS	C14:2	Tetradecadienoylcarnitine	CAR 14:2(2E,5Z)		
				CAR 14:2(2E,7Z)		
				CAR 14:2(5Z,8Z)	LMFA07070020	
	NBS	C16:1	Hexadecenoylcarnitine	CAR 16:1(2E)	LMFA07070109	
				CAR 16:1(7Z)		
				CAR 16:1(9Z)	LMFA07070097	
		C16:2	Hexadecadienoylcarnitine	CAR 16:2(2E,7Z)		
				CAR 16:2(2E,9Z)		
				CAR 16:2(7Z,10Z)	LMFA07070021	
	NBS	C18:1	Octadecenoylcarnitine	CAR 18:1(2E)		
				CAR 18:1(9Z)	LMFA07070096	
	NBS	C18:2	Octadecadienylcarnitine	CAR 18:2(2E,9Z)		
				CAR 18:2(9Z,12Z)	LMFA07070092	
	Branched	NBS	C4:0-I	Isobutyrylcarnitine	CAR 3:0;2Me	LMFA07070075
		NBS	C5:0-I	Isovalerylcarnitine	CAR 4:0;3Me	LMFA07070077
NBS		C5:0-M	2-Methylbutyrylcarnitine	CAR 4:0;2Me	LMFA07070034	
		C5:1-I	3-Methylcrotonylcarnitine	CAR 4:1(2E);3Me		
NBS		C5:1-M	Tiglylcarnitine	CAR 4:1(2E);2Me	LMFA07070108	
		C20:0-TMH	Phytanoylcarnitine*	CAR 16:0;3Me;7Me;11Me;15Me		
		C19:0-TMP	Pristanoylcarnitine*	CAR 15:0;2Me;6Me;10Me;14Me		
		C11:0-DMN	4,8-dimethylnonanoylcarnitine*	CAR 9:0;4Me;8Me		
		C9:0-DMH	2,6-dimethylheptanoylcarnitine*	CAR 7:0;2Me;6Me		
Oxidized		C3:0-OH	3-Hydroxypropionylcarnitine	CAR 3:0;3OH[S]	LMFA07070074	
	NBS	C3:0-DC	Malonylcarnitine	CAR 2:0;2COOH	LMFA07070093	
	NBS	C3:0-DC-M	Methylmalonylcarnitine	CAR 2:0;2Me;2COOH	LMFA07070094	
	NBS	C4:0-OH	3-Hydroxybutyrylcarnitine	CAR 4:0;3OH[S]	LMFA07070037	
		C4:0-OH-I	3-Hydroxyisobutyrylcarnitine	CAR 3:0;2Me;3OH[S]		
		C4:0;O	Acetoacetylcarnitine	CAR 4:0;3oxo		
		C4:0-DC	Succinylcarnitine	CAR 3:0;3COOH	LMFA07070101	
		C5:0-OH	3-Hydroxyvalerylcarnitine	CAR 5:0;3OH[S]		

NBS	C5:0-OH-I	3-Hydroxyisovalerylcarnitine	CAR 4:0;3Me;3OH[S]	LMFA07070041
NBS	C5:0-OH-M	2-Methyl-3-hydroxybutyrylcarnitine	CAR 4:0;2Me;3OH[S]	
NBS	C5:0-DC	Glutarylcarnitine	CAR 4:0;4COOH	LMFA07070091
	C5:0-M-DC	3-Methylglutarylcarnitine	CAR 4:0;3Me[R];4COOH	
	C5:1-M-DC	3-Methylglutaconylcarnitine	CAR 4:1(2E);3Me;4COOH	
	C5:0-M-OH-DC	3-Hydroxy-3-methylglutarylcarnitine	CAR 4:0;3OH[S];3Me;4COOH	
NBS	C6:0-OH	3-Hydroxy-hexanoylcarnitine	CAR 6:0;3OH[S]	LMFA07070072
	C6:0-DC	Adipylcarnitine	CAR 5:0;5COOH	LMFA07070087
	C6:1-DC	Dehydroadipylcarnitine	CAR 5:1(2E);5COOH	LMFA07070013
	C7:0-DC	Pimelylcarnitine	CAR 6:0;6COOH	
	C8:0-DC	Suberylcarnitine	CAR 7:0;7COOH	
NBS	C10:0-OH	3-Hydroxydecanoylcarnitine	CAR 10:0;3OH[S]	
NBS	C10:1-OH	3-Hydroxydecenoylcarnitine	CAR 10:1;OH	
NBS	C12:0-OH	3-Hydroxydodecanoylcarnitine	CAR 12:0;3OH[S]	LMFA07070039
	C12:0-DC	Dodecanedioylcarnitine	CAR 11:0;11COOH	LMFA07070083
NBS	C12:1-OH	3-Hydroxydodecenoylcarnitine	CAR 12:1(5Z);3OH[S]	
NBS	C14:0-OH	3-Hydroxytetradecanoylcarnitine	CAR 14:0;3OH[S]	LMFA07070045
	C14:0-DC	Tetradecanedioylcarnitine	CAR 13:0;13COOH	LMFA07070084
NBS	C14:1-OH	3-Hydroxytetradecenoylcarnitine	CAR 14:1(5Z);3OH[S] CAR 14:1(7Z);3OH[S]	
NBS	C16:0-OH	3-Hydroxyhexadecanoylcarnitine	CAR 16:0;3OH[S]	
NBS	C16:1-OH	3-Hydroxyhexadecenoylcarnitine	CAR 16:1(7Z);3OH[S] CAR 16:1(9Z);3OH[S]	LMFA07070044
	C16:0-DC	Hexadecanedioylcarnitine	CAR 15:0;15COOH	LMFA07070007
NBS	C18:0-OH	3-Hydroxystearoylcarnitine	CAR 18:0;3OH[S]	LMFA07070043
NBS	C18:1-OH	3-Hydroxyoleoylcarnitine	CAR 18:1(9Z);3OH[S]	LMFA07070025
	C18:0-DC	Octadecanedioylcarnitine	CAR 17:0;17COOH	LMFA07070085
NBS	C18:2-OH	3-Hydroxyoctadecadienoylcarnitine	CAR 18:2(9Z,12Z);3OH[S]	LMFA07070042

Note: Zero ('0') was included in newborn screening (NBS) names to unify various dialects. \* denotes mixture of unknown isomers.

### Acylcarnitine pathways

We designed a map of acylcarnitine metabolism in WikiPathways format (WP5423) to facilitate data interpretation and better orientation in various acylcarnitines' metabolic origins. The map is divided into three sections: straight-chain fatty acids, branched-chain lipids, and odd-chain fatty acids.

The straight-chain fatty acid part describes the intermediates of  $\beta$ -oxidation from stearic acid to acetyl-CoA, intermediates of oleic acid, linoleic acid,  $\alpha$ - and  $\gamma$ -linolenic acids, palmitoleic acid, docosahexaenoic and eicosapentaenoic acid complete degradation leading to acetyl-CoA,  $\omega$ - and  $\beta$ -oxidation of dicarboxylic fatty acids, and partial  $\beta$ -oxidation of eicosanoids and docosanoids illustrated by prostaglandin E2 path<sup>24-29</sup>.

The branched-chain lipids part includes  $\alpha$ - and  $\beta$ -oxidation of phytanic and pristanic acids and degradation of branched-chain fatty acids of the iso and *anteiso* series leading to intermediates of branched-chain amino acid degradation<sup>23,30,31</sup>. Amino acid-related metabolism, including ketogenesis and biotin synthesis<sup>15,21</sup>, is included to cover all metabolic origins of short-chain acylcarnitines<sup>1</sup> and branched acyl side chains of cholestanic acids are  $\beta$ -oxidized in the pathway of bile acid synthesis<sup>32</sup>. Degradation of branched-acyls leads to the production of both acetyl-CoA and propionyl-CoA and their respective acylcarnitines.

The odd-chain fatty acids part illustrates the metabolic fate of pentadecanoic acid via  $\beta$ -oxidation, leading to six molecules of acetyl-CoA and one propionyl-CoA and their acylcarnitine counterparts.

All metabolites are annotated using shorthand notation for lipid structures<sup>10,11</sup>, common names, and the most appropriate database identifiers from LIPID MAPS or the Human metabolome database. When the database contained records with (un)defined stereochemistry, the closest structure was selected. Acylcarnitines discussed in the review by Dambrova et al.<sup>1</sup> and acylcarnitines important for the pathway flow are highlighted in bold font and provided with literature citations. Metabolic conversions are depicted by arrows and enzymatic reactions yielding acylcarnitines and are highlighted in red. Five acylcarnitine transferases: carnitine acetyltransferase (CRAT), carnitine O-octanoyltransferase (CROT), carnitine palmitoyltransferase 1A (CPT1A), carnitine palmitoyltransferase 1B (CPT1B), and carnitine palmitoyltransferase 2 (CPT2) convert acyl-CoAs into acylcarnitines according to their substrate specificity, which is documented by references linked to the red arrows (and reviewed in Dambrova et al.<sup>1</sup>). Most of the pathways contain the  $\beta$ -oxidation catabolic spiral, which is composed of acyl-CoA dehydrogenase and the mitochondrial trifunctional protein (TFP)<sup>33,34</sup>. The fatty acyl-CoA dehydrogenase produces 2,3-enoyl-CoA, the TFP 2,3-enoyl-CoA hydratase adds water and yields 3-hydroxyacyl-CoA, the TFP 3-hydroxyacyl-CoA dehydrogenase oxidizes the intermediate to 3-ketoacyl-CoA, and the TFP 3-ketoacyl-CoA thiolase releases a two-carbon unit in the form of acetyl-CoA<sup>33</sup>. Carnitine-dependent peroxisomal oxidation reactions, starting with acyl-CoA oxidase, have been reviewed by Houten et al.<sup>30,32</sup>.

Carnitine acyltransferases ensure the reversible shuttling of acyl groups between free CoA and carnitine, and even the acylcarnitine forms of the intermediates can be detected using very specific and targeted techniques<sup>35</sup>. However, the stability and enzymatic accessibility of the 3-ketoacyl intermediates is much lower compared to the final acyl-CoAs and acylcarnitines, and the 3-ketoacylcarnitines are not depicted in the map for clarity. To further reduce the complexity of the pathways, enzymes involved in  $\alpha$ -,  $\beta$ -, and  $\omega$ -oxidations are omitted but can be explored in the linked WikiPathways or Reactome maps<sup>28,29</sup>. Reactions populated in the Rhea knowledgebase are annotated with a Rhea identifier<sup>36</sup>.

We created a simplified poster version of the WP5423, which can be printed on A3 format paper (Figure S1). The poster uses newborn screening-based acylcarnitine nomenclature, and the alternative systematic metabolite names can be found in Table 1.

## Conclusion

We reviewed the metabolic origins of acylcarnitines, mapped their metabolic conversions, and created a freely available WikiPathway and a poster scheme to help researchers orient themselves in the

acylcarnitine realm. We propose the use of shorthand notation for lipid structures<sup>10,11</sup> as a way to standardize the acylcarnitine reporting.

### Availability of data and materials

WikiPathway WP5423 is freely available online at <https://classic.wikipathways.org/index.php/Pathway:WP5423>

### Competing interests

The authors declare that they have no competing interests

### Funding

This study was supported by a grant from the Czech Academy of Sciences [Lumina Quaeruntur LQ200111901], by the project National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, ID Project No. LX22NPO5104) – Funded by the European Union – Next Generation EU, and by Czech Ministry of Education, Youth and Sports [LUABA22010].

### Authors' contributions - CRediT

Conceptualization: O.K.; Data curation: K.B. and O.K.; Formal analysis: J.B. and K.B.; Funding acquisition: O.K.; Investigation: J.B., K.B. and O.K.; Project administration: O.K.; Resources: K.B.; Software: O.K.; Supervision: O.K.; Validation: J.B. and K.B.; Visualization: O.K.; Writing – original draft: O.K.; Writing - review & editing: J.B., K.B. and O.K.;

### Acknowledgments

The computational resources were supplied by the project “e-Infrastruktura CZ” (e-INFRA LM2018140) provided within the program Projects of Large Research, Development, and Innovations Infrastructures.

### References

- (1) Dambrova, M.; Makrecka-Kuka, M.; Kuka, J.; Vilskersts, R.; Nordberg, D.; Attwood, M. M.; Smesny, S.; Sen, Z. D.; Guo, A. C.; Oler, E.; Tian, S.; Zheng, J.; Wishart, D. S.; Liepinsh, E.; Schioth, H. B. Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. *Pharmacol. Rev.* **2022**, *74*, 506-551.
- (2) Schooneman, M. G.; Vaz, F. M.; Houten, S. M.; Soeters, M. R. Acylcarnitines: reflecting or inflicting insulin resistance? *Diabetes* **2013**, *62*, 1-8.
- (3) Miller, M. J.; Cusmano-Ozog, K.; Oglesbee, D.; Young, S.; Committee, A. L. Q. A. Laboratory analysis of acylcarnitines, 2020 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet. Med.* **2021**, *23*, 249-258.
- (4) Cajka, T. Towards Merging Targeted and Untargeted Analysis of the Lipidome, Metabolome, and Exposome. *Lc Gc Eur* **2019**, *32*, 314-316.
- (5) Hancock, S. E.; Poada, B. L.; Batarseh, A.; Abbott, S. K.; Mitchell, T. W. Advances and unresolved challenges in the structural characterization of isomeric lipids. *Anal. Biochem.* **2017**, *524*, 45-55.

- (6) Menzel, J. P.; Young, R. S. E.; Benfield, A. H.; Scott, J. S.; Wongsomboon, P.; Cudlman, L.; Cvacka, J.; Butler, L. M.; Henriques, S. T.; Poad, B. L. J.; Blanksby, S. J. Ozone-enabled fatty acid discovery reveals unexpected diversity in the human lipidome. *Nat Commun* **2023**, *14*, 3940.
- (7) Yu, D.; Zhou, L.; Xuan, Q.; Wang, L.; Zhao, X.; Lu, X.; Xu, G. Strategy for Comprehensive Identification of Acylcarnitines Based on Liquid Chromatography-High-Resolution Mass Spectrometry. *Anal. Chem.* **2018**, *90*, 5712-5718.
- (8) Giesbertz, P.; Ecker, J.; Haag, A.; Spanier, B.; Daniel, H. An LC-MS/MS method to quantify acylcarnitine species including isomeric and odd-numbered forms in plasma and tissues. *J. Lipid Res.* **2015**, *56*, 2029-2039.
- (9) Dietzen, D. J.; Rinaldo, P.; Whitley, R. J.; Rhead, W. J.; Hannon, W. H.; Garg, U. C.; Lo, S. F.; Bennett, M. J. National academy of clinical biochemistry laboratory medicine practice guidelines: follow-up testing for metabolic disease identified by expanded newborn screening using tandem mass spectrometry; executive summary. *Clin. Chem.* **2009**, *55*, 1615-1626.
- (10) Liebisch, G.; Fahy, E.; Aoki, J.; Dennis, E. A.; Durand, T.; Ejsing, C. S.; Fedorova, M.; Feussner, I.; Griffiths, W. J.; Kofeler, H.; Merrill, A. H., Jr.; Murphy, R. C.; O'Donnell, V. B.; Oskolkova, O.; Subramaniam, S.; Wakelam, M. J. O.; Spener, F. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. *J. Lipid Res.* **2020**, *61*, 1539-1555.
- (11) Kopczynski, D.; Hoffmann, N.; Peng, B.; Liebisch, G.; Spener, F.; Ahrends, R. Goslin 2.0 Implements the Recent Lipid Shorthand Nomenclature for MS-Derived Lipid Structures. *Anal. Chem.* **2022**, *94*, 6097-6101.
- (12) Liebisch, G.; Vizcaino, J. A.; Kofeler, H.; Trotsmuller, M.; Griffiths, W. J.; Schmitz, G.; Spener, F.; Wakelam, M. J. O. Shorthand notation for lipid structures derived from mass spectrometry. *J. Lipid Res.* **2013**, *54*, 1523-1530.
- (13) Vondrackova, M.; Kopczynski, D.; Hoffmann, N.; Kuda, O. LORA, Lipid Over-Representation Analysis Based on Structural Information. *Anal. Chem.* **2023**, *95*, 12600-12604.
- (14) Li, J. M.; Li, L. Y.; Zhang, Y. X.; Jiang, Z. Y.; Limbu, S. M.; Qiao, F.; Degrace, P.; Chen, L. Q.; Zhang, M. L.; Du, Z. Y. Functional differences between l- and d-carnitine in metabolic regulation evaluated using a low-carnitine Nile tilapia model. *Br. J. Nutr.* **2019**, *122*, 625-638.
- (15) Soeters, M. R.; Serlie, M. J.; Sauerwein, H. P.; Duran, M.; Ruiten, J. P.; Kulik, W.; Ackermans, M. T.; Minkler, P. E.; Hoppel, C. L.; Wanders, R. J.; Houten, S. M. Characterization of D-3-hydroxybutyrylcarnitine (ketocarnitine): an identified ketosis-induced metabolite. *Metabolism* **2012**, *61*, 966-973.
- (16) Liu, H.; Tan, D.; Han, L.; Ye, J.; Qiu, W.; Gu, X.; Zhang, H. A new case of malonyl-CoA decarboxylase deficiency with mild clinical features. *Am. J. Med. Genet. A* **2016**, *170A*, 1347-1351.
- (17) Roe, C. R.; Millington, D. S.; Maltby, D. A. Identification of 3-methylglutaryl-carnitine. A new diagnostic metabolite of 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency. *J. Clin. Invest.* **1986**, *77*, 1391-1394.
- (18) Peters, H.; Ferdinandusse, S.; Ruiten, J. P.; Wanders, R. J.; Boneh, A.; Pitt, J. Metabolite studies in HIBCH and ECHS1 defects: Implications for screening. *Mol. Genet. Metab.* **2015**, *115*, 168-173.
- (19) Vaclavik, J.; Madrova, L.; Kouril, S.; de Sousa, J.; Brumarova, R.; Janeckova, H.; Jacova, J.; Friedecky, D.; Knapkova, M.; Kluijtmans, L. A. J.; Grunert, S. C.; Vaz, F. M.; Janzen, N.; Wanders, R. J. A.; Wevers, R. A.; Adam, T. A newborn screening approach to diagnose 3-hydroxy-3-methylglutaryl-CoA lyase deficiency. *JIMD Rep* **2020**, *54*, 79-86.
- (20) Hattori, T.; Notsu, Y.; Tanaka, M.; Matsui, M.; Iida, T.; Watanabe, J.; Osawa, Y.; Yamaguchi, S.; Yano, S.; Taketani, T.; Kobayashi, H. A Simple Flow Injection Analysis-Tandem Mass Spectrometry Method to Reduce False Positives of C5-Acylcarnitines Due to Pivaloylcarnitine Using Reference Ions. *Children (Basel)* **2022**, *9*.

- (21) Lin, S.; Hanson, R. E.; Cronan, J. E. Biotin synthesis begins by hijacking the fatty acid synthetic pathway. *Nat. Chem. Biol.* **2010**, *6*, 682-688.
- (22) Taormina, V. M.; Unger, A. L.; Schiksnis, M. R.; Torres-Gonzalez, M.; Kraft, J. Branched-Chain Fatty Acids-An Underexplored Class of Dairy-Derived Fatty Acids. *Nutrients* **2020**, *12*.
- (23) Wallace, M.; Green, C. R.; Roberts, L. S.; Lee, Y. M.; McCarville, J. L.; Sanchez-Gurmaches, J.; Meurs, N.; Gengatharan, J. M.; Hover, J. D.; Phillips, S. A.; Ciaraldi, T. P.; Guertin, D. A.; Cabrales, P.; Ayres, J. S.; Nomura, D. K.; Loomba, R.; Metallo, C. M. Enzyme promiscuity drives branched-chain fatty acid synthesis in adipose tissues. *Nat. Chem. Biol.* **2018**, *14*, 1021-1031.
- (24) Hadjiagapiou, C.; Sprecher, H.; Kaduce, T. L.; Figard, P. H.; Spector, A. A. Formation of 8-hydroxyhexadecatrienoic acid by vascular smooth muscle cells. *Prostaglandins* **1987**, *34*, 579-589.
- (25) Diczfalusy, U. Beta-oxidation of eicosanoids. *Prog. Lipid Res.* **1994**, *33*, 403-428.
- (26) Johnson, M.; Davison, P.; Ramwell, P. W. Carnitine-dependent  $\beta$  Oxidation of Prostaglandins. *J. Biol. Chem.* **1972**, *247*, 5656-5658.
- (27) Balas, L.; Rise, P.; Gandrath, D.; Rovati, G.; Bolego, C.; Stellari, F.; Trenti, A.; Buccellati, C.; Durand, T.; Sala, A. Rapid Metabolization of Protectin D1 by beta-Oxidation of Its Polar Head Chain. *J. Med. Chem.* **2019**, *62*, 9961-9975.
- (28) Gillespie, M. E.; Reactome, release 86, 10.3180/REACT\_1473.1, 2003.
- (29) Jassal, B.; Reactome, release 86, 10.3180/REACT\_16880.1, 2009.
- (30) Houten, S. M.; Wanders, R. J. A.; Ranea-Robles, P. Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism. *Biochim Biophys Acta Mol Basis Dis* **2020**, *1866*, 165720.
- (31) van den Brink, D. M.; Wanders, R. J. Phytanic acid: production from phytol, its breakdown and role in human disease. *Cell. Mol. Life Sci.* **2006**, *63*, 1752-1765.
- (32) Ferdinandusse, S.; Houten, S. M. Peroxisomes and bile acid biosynthesis. *Biochim. Biophys. Acta* **2006**, *1763*, 1427-1440.
- (33) Wang, Y.; Palmfeldt, J.; Gregersen, N.; Makhov, A. M.; Conway, J. F.; Wang, M.; McCalley, S. P.; Basu, S.; Alharbi, H.; St Croix, C.; Calderon, M. J.; Watkins, S.; Vockley, J. Mitochondrial fatty acid oxidation and the electron transport chain comprise a multifunctional mitochondrial protein complex. *J. Biol. Chem.* **2019**, *294*, 12380-12391.
- (34) Houten, S. M.; Wanders, R. J. A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation. *J. Inherit. Metab. Dis.* **2010**, *33*, 469-477.
- (35) Kuerschner, L.; Leyendecker, P.; Klizaitė, K.; Fiedler, M.; Saam, J.; Thiele, C. Development of oxaalkyne and alkyne fatty acids as novel tracers to study fatty acid beta-oxidation pathways and intermediates. *J. Lipid Res.* **2022**, *63*, 100188.
- (36) Bansal, P.; Morgat, A.; Axelsen, K. B.; Muthukrishnan, V.; Coudert, E.; Aimo, L.; Hyka-Nouspikel, N.; Gasteiger, E.; Kerhornou, A.; Neto, T. B.; Pozzato, M.; Blatter, M. C.; Ignatchenko, A.; Redaschi, N.; Bridge, A. Rhea, the reaction knowledgebase in 2022. *Nucleic Acids Res.* **2022**, *50*, D693-D700.